

ORIGINAL ARTICLE

Predictors of Persistent Carbapenem-Resistant Enterobacteriaceae Carriage upon Readmission and Score Development

Pnina Ciobotaro, MD;^{1,2,3,a} Natalie Flaks-Manov, MPH;^{3,a} Maly Oved, MPA;^{1,2} Ami Schattner, MD;^{2,4} Moshe Hoshen, PhD;³ Eli Ben-Yosef, MPH;^{2,5} Ran D. Balicer, MD, PhD, MPH;^{3,6} Oren Zimhony, MD^{1,2}

BACKGROUND. Carriers of carbapenem-resistant Enterobacteriaceae (CRE) are often readmitted, exposing patients to CRE cross-transmission.

OBJECTIVE. To identify predictors of persistent CRE carriage upon readmission, directing a risk prediction score.

DESIGN. Retrospective cohort study.

SETTING. University-affiliated general hospital.

PATIENTS. A cohort of 168 CRE carriers with 474 readmissions.

METHODS. The primary and secondary outcomes were CRE carriage status at readmission and length of CRE carriage. Predictors of persistent CRE carriage upon readmission were analyzed using a generalized estimating equations (GEE) multivariable model. Readmissions were randomly divided into derivation and validation sets. A CRE readmission score was derived to predict persistent CRE carriage in 3 risk groups: high, intermediate, and low. The discriminatory ability of the model and the score were expressed as C statistics.

RESULTS. CRE carrier status persisted for 1 year in 33% of CRE carriers. Positive CRE status was detected in 202 of 474 readmissions (42.6%). The following 4 variables were associated with persistent CRE carriage at readmission: readmission within 1 month (odds ratio [OR], 6.95; 95% confidence interval [CI], 2.79–17.30), positive CRE status on preceding admission (OR, 5.46; 95% CI, 3.06–9.75), low Norton score (OR, 3.07; 95% CI, 1.26–7.47), and diabetes mellitus (OR, 1.84; 95% CI, 0.98–3.44). The C statistics were 0.791 and 0.789 for the derivation set (n = 322) model and score, respectively, and the C statistic was 0.861 for the validation set of the score (n = 152). The rates of CRE carriage at readmissions (validation set) for the groups with low, intermediate, and high scores were 8.6%, 38.9%, and 77.6%, respectively.

CONCLUSIONS. CRE carrier state commonly persists upon readmission, and this risk can be estimated to guide screening policy and infection control measures.

Infect. Control Hosp. Epidemiol. 2016;37(2):188–196

Infections caused by carbapenem-resistant Enterobacteriaceae (CRE), mostly carbapenem-resistant *Klebsiella pneumoniae* (CRKP) species, are a major public health threat worldwide.^{1–5} Available therapeutic options are scarce⁶ and are of disputed efficacy.⁷ The attributable mortality rate of CRKP infections ranges from 37% to 50% globally.^{2,8,9} Special enhanced infection control measures that include cohorting of carriers and treatment by a dedicated staff have been introduced to limit the spread of CRE.^{10–13} Containment of CRE transmission in Israel was strongly correlated with compliance with these guidelines and in some reports with screening for CRE carrier status.^{10,14}

CRE carriers often have poor functional status^{2,15} and are prone to hospital readmissions,^{15–17} creating a significant, though highly variable, risk for cross-transmission

(6%–58%).^{12,18,19} Identifying the CRE carrier status upon admission by rectal culture is a precautionary measure, yet it requires 48–72 hours from sample collection to final results.²⁰ Molecular methods are attractive alternatives²¹; however, their availability is limited and cost-effectiveness is uncertain.

One of the vexing challenges for inpatient management of CRE-colonized patients is the empirical determination of infection control measures for returning CRE carriers. Patients with prolonged CRE carriage present a constant risk of CRE transmission to other hospital patients; therefore, it is critical that carriers are isolated within a CRE cohort. If a persistent CRE carrier is incorrectly assigned out of the CRE cohort, he or she is placing other patients at risk for cross transmission. If a patient is identified as being CRE positive, an intrahospital

Affiliations: 1. Infectious Diseases Unit, Kaplan Medical Center, Rehovot, Israel; 2. Hebrew University Hadassah Medical School, Jerusalem, Israel; 3. Clalit Research Institute, Chief Physician's Office, Clalit Health Services, Tel-Aviv, Israel; 4. Department of Medicine, Kaplan Medical Center, Rehovot, Israel; 5. Computer Department, Kaplan Medical Center, Rehovot, Israel; 6. Epidemiology Department, Ben-Gurion University, Beer-Sheva, Israel.

^aAuthors with equal contribution.

Received June 8, 2015; accepted October 16, 2015

© 2016 by The Society for Healthcare Epidemiology of America. All rights reserved. 0899-823X/2016/3702-0010. DOI: 10.1017/ice.2015.278




FIGURE 1. Study enrolment of 168 carbapenem-resistant Enterobacteriaceae (CRE) carriers with 474 readmissions. A total of 496 patients were identified as CRE carriers (index hospitalization) in Kaplan Medical Center (KMC) throughout 2006–2012, the study period. A total of 168 of the CRE carriers were readmitted with overall 474 readmissions. In 202 of these readmissions (42.6%), the patients had positive CRE cultures indicating persistent carriage.

transfer into the CRE cohort would be required, and former roommates need to be tested for possible CRE cross transmission. Conversely, a past carrier of CRE who is placed within the CRE cohort, but is later identified as CRE negative from the readmission screening, is at a higher risk of reacquiring CRE. Moreover, detectable CRE carriage can fluctuate, and recurring CRE detection has been reported.²² Recurrence can be related to either reacquisition or to a false-negative test result upon readmission arrival, reflecting a transient decrease in bacterial counts below the detection limit. Thus, the primary prediction of CRE carriage risk upon readmission has implications for the ensuing hospitalization. This information can be used to guide appropriate infection control measures from the outset as well as additional follow-up screening to detect recurrence of CRE carriage.

Although predictors for CRE acquisition have been studied,^{2,8,23} the predictors for carriage of CRE upon readmission remain poorly defined.^{22,24–26} We conducted a retrospective cohort study of CRE carriers who were readmitted to identify predictors for persistent CRE carriage and to develop a prediction score to estimate this risk.

METHODS

Setting and Data Sources

Kaplan Medical Center (KMC) is a 535-bed, university-affiliated general hospital with 42,500 adult admissions annually and a 30-day readmission rate of 17.7%. An

intervention program for CRE containment was implemented at KMC in February 2007.¹² The Infectious Diseases Unit maintains a detailed computerized database of CRE carriers. In addition, clinical data were collected from KMC's electronic health records. The study was approved by the KMC Institutional Review Board.

Study Design and Population

This retrospective cohort study included all readmissions of patients who were identified as CRE carriers at an index hospitalization with at least 1 readmission to KMC between January 1, 2006, and December 31, 2012 (Figure 1). A CRE carrier was defined as any patient who had a CRE-positive culture, obtained either rectally at screening or clinically (based on the patient's medical status). When tested at the time of readmission, patients could have either a positive CRE culture (positive CRE status, persistent carrier) or a negative CRE culture (negative CRE status). From June 2007, any patient with a history of CRE carriage was rescreened for CRE upon readmission. Infection control measures implemented prior to CRE screening results were determined at the discretion of the infection control unit.

Microbiologic Analysis

CRE isolates were identified using the VITEK2 automated microbiology system (bioMérieux, Marcy l'Etoile, France), CHROMagar KPC (Hy-Labs, Rehovot, Israel),²⁷ and the

modified Hodge test²⁸ according to Clinical and Laboratory Standards Institute guidelines.²⁹ Antibiotic susceptibility profiling was performed automatically using the VITEK 2 system, and epsilon tests (Etests) were used to determine the minimal inhibitory concentration for the carbapenems colistin and tigecyclin.

Outcome Variables

The primary outcome was CRE carriage at readmission and the secondary outcome was length of CRE carriage.

CRE Predictor Variables

Different variables were tested as possible predictors of CRE carriage at readmission: demographic characteristics, origin of admission [home or long-term care facility (LTCF)], chronic comorbidities, source of CRE culture (screening/clinical culture), variables from preceding admissions (CRE carriage status, medical status, antibiotic treatment), time between last discharge and the current admission, clinical status on readmission, and Norton score (Table 1).

The Norton score³⁰ predicts the risk of pressure sore development and ranges between 5 to 20: low (<10) indicates very high risk, 10–14 indicates high risk, 15–18 indicates intermediate risk, and high (>18) indicates low risk. The intermediate-risk and low-risk groups (Norton score >14) were combined because the rate of CRE positive cultures was similar for these 2 risk groups. For readmissions with a missing Norton score (7.2%), we assigned a Norton score >14 based on the observation that the rate of CRE positivity for these patients is similar to that group.

Statistical Analysis

We calculated descriptive statistics for the predictor variables for all readmissions of patients who were CRE carriers at an index hospitalization. Univariate analysis by χ^2 test was applied for categorical variables and by ANOVA test for continuous variables. All analyses were performed using SPSS software (version 20).

Prediction model development and validation. A multivariable analysis using the generalized estimating equations (GEE) model^{31,32} was used to assess whether the variables found in the univariate analysis were significantly associated with CRE carriage at readmission. The GEE model accounts for clustering of multiple admissions among patients. We used a split sample design to derive and internally validate the prediction model. Patients were randomly assigned to either the derivation set (~70%, n = 322) or validation set (~30%, n = 152). Readmissions of a given patient could be considered for only 1 set.

We used the GEE analysis on the derivation set and employed the estimated probability of CRE carriage as a discriminant for positive CRE carriage, which we evaluated using the C statistic (ie, the probability that predicting the outcome is better than chance).

A prediction score was derived for CRE carriage on readmission, a CRE readmission score (CRE-RS), according to the variables identified in the GEE analysis. To form a convenient and rounded point score, we multiplied each of the model coefficients by 2. The integer values from all applicable factors were then added to estimate a total score for each patient. These scores ranged from 0 to 10 and were divided into 3 risk categories; higher scores indicated increasing probability for CRE carriage at readmission.

The developed CRE-RS was tested on the derivation set and was compared with the GEE model to determine accuracy. To confirm its possible utility, we tested its categories on the validation set.

Duration of carriage. The duration of CRE carriage from the first positive CRE culture to the last readmission with negative CRE culture (indicating clearance) or until the last readmission with positive CRE culture (indicating persistence) was estimated using the Kaplan-Meier survival model.

RESULTS

Readmitted Patients

During the 7-years of the study period, 496 CRE carriers were admitted to KMC. Among them, 168 CRE carriers, accounting for a total of 474 readmissions, were eligible for the study (Figure 1). Among the 168 CRE carriers with readmissions, 59% were women and 57% were aged 80 or older. CRE strains included *Klebsiella pneumoniae* (163 patients), *Enterobacter cloacae* (2 patients), and *Enterobacter amnigenus*, *Escherichia coli*, and *Klebsiella oxytoca* (1 patient each). Of these patients, 60% had ≥ 2 readmissions during the study period. The 30-day readmission rate of CRE carriers was 43.5%, compared with only 17.7% readmission rate to KMC during the study period.

Predictors of CRE Carriage at Readmission on Univariate Analysis

For 202 of the 474 readmissions (42.6%), the CRE status was positive, involving 91 of the 168 CRE carriers. Of the 202 positive CRE readmissions, 185 readmissions were detected by screening cultures. Overall, 15 demographic and clinical variables in the univariate analysis were statistically significant predictors of CRE carriage at readmission. The rate of positive CRE cultures at readmission declined with time from the last discharge, decreasing from 53.4% (110 of 202) among those who returned within 1 month to 15.3% (11 of 202) among those who returned ≥ 7 months after the index admission ($P < 0.001$). CRE carriage at readmission was correlated with increasing age and readmission from an LTCF. More than half (51.7%) of the CRE carriers who were readmitted from an LTCF (37.1% of the readmissions) had CRE positive cultures, as opposed to 37.3% in patients who were readmitted from their homes ($P = 0.009$).

Colonization with other resistant bacteria, antimicrobial therapy on preceding hospitalization, and several chronic

TABLE 1. Characteristics of 474 Readmissions of Carbapenem-Resistant Enterobacteriaceae (CRE) Carrier Patients (n = 168) and Results of an Univariate Risk Factors Analysis for Being Persistent CRE Carrier on Readmission

Risk Factor	Readmissions (n = 474), No. (%)	Readmissions with CRE + Culture (n = 202), No. (% of Readmissions)	Odds Ratio (95% Confidence Interval)	P Value
Age				
18–59 years	56 (11.8)	20 (35.7)	1.0	.002
60–69 years	88 (18.6)	37 (42.0)	1.3 (0.7–2.5)	
70–79 years	118 (24.9)	36 (30.5)	0.8 (0.4–1.5)	
80–89 years	165 (34.8)	77 (46.7)	1.6 (0.9–2.9)	
90+ years	47 (9.9)	32 (68.1)	3.8 (1.7–8.5)	
Origin of admission^a				
Home	287 (60.5)	107 (37.3)	1.0	.009
LTCF	176 (37.1)	91 (51.7)	1.8 (1.2–2.6)	
Comorbidity				
Diabetes mellitus	249 (52.5)	128 (51.4)	2.2 (1.5–3.1)	<.001
Chronic renal failure	82 (17.3)	48 (58.5)	2.2 (1.3–3.5)	.001
Dialysis	35 (7.4)	21 (60.0)	2.1 (1.1–4.3)	.031
Heart failure	93 (19.6)	40 (41.2)	0.5 (0.3–0.9)	.76
Malignancy	100 (21.1)	38 (38.0)	0.8 (0.5–1.2)	.29
Variables on preceding admission				
Wounds	51 (10.8)	28 (54.9)	1.7 (1.0–3.1)	.06
Invasive procedure	105 (22.2)	53 (50.5)	1.5 (1.0–2.3)	.065
Colonization with other resistant bacteria	137 (28.9)	71 (51.8)	1.7 (1.1–2.5)	.01
Any antibiotics	244 (51.5)	120 (49.2)	1.7 (1.2–2.5)	.003
Duration of preceding admission				
1–7 days	325 (68.6)	134 (41.2)	1.0	.79
8–14 days	87 (18.4)	44 (50.6)	1.5 (0.9–2.3)	
≥15 days	62 (13.1)	24 (38.7)	0.9 (0.5–1.6)	
Time from last discharge				
<1 month	206 (43.5)	110 (53.4)	6.4 (3.2–12.7)	<.001
1–3 months	145 (30.6)	64 (44.1)	4.4 (2.1–8.9)	
4–6 months	51 (10.8)	17 (33.3)	2.8 (1.2–6.6)	
≥7 months	72 (15.2)	11 (15.3)	1.0	
Time from CRE culture disclosure				
<1 month	68 (14.3)	47 (69.1)	5.1 (2.9–9.2)	<.001
1–3 months	111 (23.4)	56 (50.5)	2.3 (1.5–3.7)	
4–6 months	63 (13.3)	30 (47.6)	2.1 (1.2–3.7)	
≥7 months	234 (49.4)	71 (30.3)	1.0	
Characteristics at readmission				
Unconsciousness	81 (17.1)	45 (55.6)	1.7 (1.1–2.8)	.001
Dependence (eating, bathing, receiving medications)	379 (80.0)	181 (47.8)	3.2 (1.9–5.4)	<.001
Urinary catheter	177 (37.3)	99 (55.9)	2.4 (1.6–3.5)	<.001
Norton score^b				
<10	87 (18.4)	48 (55.2)	3.0 (1.8–5.2)	<.001
10–14	235 (49.6)	110 (46.8)	2.2 (1.4–3.3)	
>14	152 (32.1)	44 (28.9)	1.0	
CRE status on preceding admission^c				
Positive	291 (61.4)	175 (60.1)	8.7 (5.4–14.0)	<.001
Negative	183 (38.6)	27 (14.8)	1.0	
Source of CRE culture on preceding admission				
Clinical culture	104 (21.9)	58 (55.8)	1.0	<.001
Rectal culture (screening)	187 (39.5)	117 (62.6)	1.3 (0.9–2.1)	
None	183 (38.6)	27 (14.8)	0.1 (0.1–0.2)	

NOTE. CRE, carbapenem-resistant Enterobacteriaceae; LTCF, long-term care facility.

^aData missing for 11 readmissions.

^bNorton pressure sore risk assessment score; high Norton score (>14): low–medium risk; medium Norton score (10–14): high risk; low Norton score (<10): very high risk.³⁰

^cAll readmissions were of positive CRE carriers on their index hospitalization. On readmission, cultures could be either positive or negative for CRE.

TABLE 2. Risk Factors of Carbapenem-Resistant Enterobacteriaceae (CRE) Carriage on Readmissions of Known CRE Carriers in the Final Multivariable Model

Risk Factor	Coefficient	Odds Ratio (95% CI)	P Value	Calculated Score (CRE-RS)
Time from last discharge				
<1 month	1.94	6.95 (2.79–17.30)	<.001	4
1–3 months	1.76	5.82 (1.8–18.88)	.003	4
4–6 months	1.18	3.25 (1.0–1.53)	.05	2
≥7 months		1.00		0
CRE status on preceding admission^a				
Positive	1.7	5.46 (3.06–9.75)	<.001	3
Negative		1.00		0
Norton score^b				
<10	1.12	3.07 (1.26–7.47)	.013	2
10–14	0.61	1.84 (1.09–3.12)	.023	1
>14		1.00		0
Diabetes mellitus				
Yes	0.61	1.84 (0.98–3.44)	.058	1
No		1.00		0

NOTE. Values are given for proportions with coefficients, odds ratio and *P* values. A calculated score for prediction of CRE carriage on readmission was derived from the coefficients.

CRE, carbapenem-resistant Enterobacteriaceae; CRE-RS, CRE readmission score.

^aAll readmissions were of patients found to be CRE carriers on their index hospitalization. On the preceding readmission, cultures could be either positive or negative for CRE.

^bNorton pressure sore risk assessment score; high Norton score (>14): low–medium risk; medium Norton score (10–14): high risk; low Norton score (<10): very high risk.³⁰

comorbidities were also significantly associated with CRE carriage upon readmission. Additional results are presented in Table 1.

Predictors of CRE Carriage upon Readmission on Multivariable Analysis

Using a GEE analysis, 4 factors were found upon readmission to significantly predict CRE carriage: readmission within 1 month since the last discharge (OR, 6.95; *P* < 0.001; 95% CI, 2.79–17.30), positive CRE status at the preceding admission (OR, 5.46; *P* < 0.001; 95% CI, 3.06–9.75), low Norton score (OR, 3.07; *P* = 0.013; 95% CI, 1.26–7.47), and diabetes mellitus diagnosis (OR, 1.84; *P* = 0.058; 95% CI, 0.98–3.44) (Table 2). In the univariate analysis, patient age, admission from a LTCF, and the presence of wounds were related to CRE carriage on readmission; these variables were not significant in the GEE analysis. This finding is likely due to the high correlation of these variables with the Norton score (multicollinearity phenomena; data not shown). The *C* statistic for the GEE model in the derivation set was 0.791 (95% CI, 0.741–0.841) (Figure 2).

Prediction Score Derivation and Validation

A CRE-RS was established based on the predicting variables identified in the GEE model. The *C* statistic for the derivation set of the score was 0.789 (95% CI, 0.739–0.839). The curves of the GEE model and the CRE-RS nearly overlapped, indicating very close performance of the proposed score and the

multivariable model. The *C* statistic for the validation set of the score was 0.861 (95% CI, 0.803–0.920) (Figure 2).

The risk of persistent CRE carriage on readmission ranged from 0 to 76% in each risk category according to the derivation set illustrated in Figure 3. The proximity between the risks in several risk categories enabled us to group the 11 risk points (0–10) into low (0–5), intermediate (6–7), and high (8–10) risk groups. For a patient in the high-risk group, the risk for positive CRE culture on readmission was 70.2% (95% CI, 60.9–78.4) in the derivation set and 77.6% (95% CI, 66.6–86.4) in the validation set. For a patient in the low-risk group, the risk for CRE carriage on readmission was 14.6% in the derivation set (95% CI, 9.2–21.6) and 8.6% in the validation set (95% CI, 2.9–19.0). The groups with low and high scores constituted 78% (251 of 322) or 88% (134 of 152) of the readmissions in the derivation and validation sets, respectively. The remaining readmissions with intermediate scores (6–7) had a 43.7% risk (95% CI, 31.9–56.0) for CRE carriage upon readmission in the derivation set and a 38.9% risk (95% CI, 17.3–64.3) in the validation set (Table 3).

Duration of CRE Carriage

A Kaplan-Meier curve for CRE carriage was derived for the 168 CRE carriers (Figure 4). The mean time to CRE clearance was 324 days (95% CI, 254–395 days) and the median time to CRE




FIGURE 2. Receiver operating characteristics (ROC) curves of the generalized estimating equations (GEE) model. The GEE model of the derivation set is compared to the carbapenem-resistant Enterobacteriaceae readmission scores (CRE-RS) of the derivation set and validation set.




FIGURE 3. Risk assessment of carbapenem-resistant Enterobacteriaceae (CRE) carriage. The proposed carbapenem-resistant Enterobacteriaceae readmission score (CRE-RS) of the derivation set ranges between 0 and 10. The bars show the proportion of readmissions of CRE carriers with positive CRE cultures in every risk score category. The circles and the triangles show the absolute numbers of CRE carriers' readmissions and CRE carriers' readmissions with positive CRE cultures, respectively.

TABLE 3. Grouped Risk Categories of Carbapenem-Resistant Enterobacteriaceae Carriage on Readmission of the Proposed Carbapenem-Resistant Enterobacteriaceae Readmission Score (CRE-RS) in the Derivation and Validation Sets

CRE- Readmission Score (CRE-RS)	Risk Category	Readmissions in Each Category (%)	Readmissions with Positive CRE Cultures (%)	Risk of Persistent CRE Carriage on Readmission, % (95% Confidence Interval)
Derivation set		322 (100)	131 (100)	40.7 (35.3–46.3)
0–5	Low	137 (42.5)	20 (15.3)	14.6 (9.2–21.6)
6–7	Intermediate	71 (22.0)	31 (23.7)	43.7 (31.9–56.0)
8–10	High	114 (35.4)	80 (61.1)	70.2 (60.9–78.4)
Validation set		152 (100)	71 (100)	46.7 (38.6–55.0)
0–5	Low	58 (38.2)	5 (7)	8.6 (2.9–19.0)
6–7	Intermediate	18 (11.8)	7 (9.9)	38.9 (17.3–64.3)
8–10	High	76 (50)	59 (83.1)	77.6 (66.6–86.4)

NOTE. CRE, carbapenem-resistant Enterobacteriaceae; CRE-RS, carbapenem-resistant Enterobacteriaceae readmission score.




FIGURE 4. Kaplan-Meier curve for cumulative survival function of carbapenem-resistant Enterobacteriaceae (CRE) clearance. The curve shows time until the CRE screening and clinical cultures of 168 CRE carriers were negative upon 474 readmissions.

clearance was 190 days (95% CI, 123–257 days). One year after the index hospitalization, approximately one-third of patients remained CRE carriers at readmission; 2 years after the index hospitalization, 15% remained CRE carriers. Ultimately, CRE carriage may extend up to 30 months after the index hospitalization.

DISCUSSION

CRE carriers are often elderly patients with multiple comorbidities^{2,15} who tend to experience rehospitalizations,^{15–17} which consequently pose a threat of cross infection of CRE. Therefore, prediction of CRE carrier status upon readmission is important for supporting screening policies and infection control measures.

Our study identified 4 factors that significantly predict risk of persistent CRE carriage at readmission with strong

discrimination: short time from the last discharge, positive CRE status on preceding admission, low Norton score, and diabetes mellitus.

Our finding that one-third of the patients in which CRE carriage persisted 1 year after their index hospitalization is alarming, although the results are in accord with those of other recent studies. One study showed that 39% of CRE carriers still presented positive CRE cultures 1 year after hospitalization.²⁴ In another study, 30% of CRE carriers residing in LTCFs remained positive after 10 months.²⁶ Furthermore, our study showed that CRE carriage can be very long, up to 30 months.

As stated, readmissions of CRE-positive patients are common; 60% had ≥ 2 readmissions in our cohort. The 30-day readmission rate is also as high as 43.5%, more than twice the general rate for readmissions during the study period and in a previous study at KMC.³³ More than half (53.4%) of these patients were still positive for CRE, creating a substantial burden for the healthcare system.

According to previous studies, the risk factors for prolonged CRE carriage among LTCF residents included antibiotic exposure within the preceding 3 months and screening within 90 days of the first positive culture results.²⁶ The presence of any catheter, LTCF residency, low functional status, and Charlson score were risk factors of persistent CRE carriage after discharge.²² Another study, which also included outpatients, revealed that previous hospitalizations and clinical CRE cultures, rather than screening cultures, predict prolonged CRE carriage.²⁴ Our study focused on readmissions to an acute care hospital in which readmitted patients presented with worsening clinical conditions that were likely associated with higher rates of persistent CRE carriage.

The predictor variable for CRE carriage on readmission with the highest odds ratio was time from last discharge. The shorter the time between admissions, the higher the odds ratio for CRE carriage. Conversely, it is plausible that a patient who does not require readmission for a longer time is less likely to maintain resistant bacteria that are associated with increased morbidity and poor general condition. The second ranked factor was positive CRE status at the preceding admission

indicating that this factor is a major predictor of carriage on subsequent admission. The third ranked factor was a low Norton score, which predicts the potential patients who will develop pressure sores.³⁰ The Norton score has also proven useful for predicting rehabilitation outcome and post-surgery complications.^{34,35} Few studies have examined the role of the Norton score as a predictor of resistant bacteria carriage,^{26,36} and our study is the first, to our knowledge, to describe the utility of this score in the prediction of persistent CRE carriage. The susceptibility of patients at high risk of pressure sores for resistant bacteria carriage can be ascribed to healthcare institution admissions and increased nursing needs, which create more opportunities for cross-transmission in bedridden patients who often require antimicrobial therapy.^{37,38} Finally, diabetes mellitus was examined as a predictor for the multivariable prediction model despite its borderline statistical significance because it is a known risk factor for CRE and other resistant bacteria carriage.³⁹ Diabetes was previously suggested, using univariate analysis, to increase the risk of CRE carriage by 10%–45%^{2,9}; our univariate analysis results are in accord with these findings (Table 1).

The weighted scores of these variables allow for the derivation of a total point score for each patient. The overlapping receiver operating characteristics (ROC) curves of the derivation and validation sets of the score showed that the model calibration was reliable and that the percentage of CRE positive cultures was strongly correlated with the proposed CRE-RS. None of the strata were significantly different between the derivation and validation sets.

A high CRE-RS of 8–10 points predicted positive carriage state in 77.6% of readmissions in the validation set (Table 3). This high score signifies a strong indication for the enhanced precautions used for CRE carriers.^{10–12} In contrast, patients with a low score of ≤ 5 points have low probability of CRE carriage (8.6% in the validation set). The high and low scoring groups, which bear high certainty of their predicted CRE status on readmission, comprise 88% of the readmitted CRE carriers (Table 3). For patients with an intermediate score of 6–7 points, application of contact precautions (as for other resistant bacteria carriers) and a single-patient room (if possible) while results of CRE screening are pending is a reasonable approach to preventing cross-infection. Derivation of CRE-RS upon every readmission can enable adjustment of the precautions needed.

The identified predictors and the derived score present several potential advantages for healthcare providers. First, these predictors are readily and immediately accessible in hospital medical databases when a patient is admitted. Second, allocation of patients to the most appropriate isolation setting upon arrival, while screening results are pending, would reduce intrahospital transfers, which are time-consuming and adversely affect patient management.⁴⁰ Third, it would reduce cross infection to roommates. Fourth, institutions with limited resources may prioritize screening for patients with an intermediate score. Finally, CRE-RS may guide the frequency of

follow-up CRE screening cultures for patients with either intermediate or high scores that were negative for CRE on initial screening at readmission. These patients may be more prone to reacquisition or more likely to experience reamplification of underdetected CRE strains. They also may require further testing for CRE conversion as well as additional enhanced precautions during long hospitalizations or while in LTCFs.

This study shows that prediction of a patient's CRE carrier status upon readmission to the hospital can be achieved with reasonable accuracy and can direct infection control measures and inform rescreening decisions in real time. Additionally, a scoring tool can guide the administration of follow-up cultures in known past CRE carriers who tested negative upon initial screening.

ACKNOWLEDGMENTS

We thank Dimitri Drapkin for his technical assistance in data extraction; Harel Eilat for his editing support; and Chandra Cohen, Jenna Berent and Sydney Krispin for their critical reviews of the article.

Financial support. No financial support was provided relevant to this article.

Potential conflicts of interest. All authors report no conflicts of interest relevant to this article.

Address correspondence to Pnina Ciobotaro, MD, Infectious Diseases Unit, Kaplan Medical Center, P.O. Box 1, Rehovot, Israel (Pninci@clalit.org.il) or Zimhony Oren, MD, Infectious Diseases Unit, Kaplan Medical Center, P.O.B. 1, Rehovot, Israel (oren_z@clalit.org.il).

REFERENCES

- Schwaber MJ, Carmeli Y. Carbapenem-resistant Enterobacteriaceae: a potential threat. *JAMA* 2008;300:2911–2913.
- Schwaber MJ, Klarfeld-Lidji S, Navon-Venezia S, Schwartz D, Leavitt A, Carmeli Y. Predictors of carbapenem-resistant *Klebsiella pneumoniae* acquisition among hospitalized adults and effect of acquisition on mortality. *Antimicrob Agents Chemother* 2008;52:1028–1033.
- Nordmann P, Naas T, Poirel L. Global spread of Carbapenemase-producing Enterobacteriaceae. *Emerg Infect Dis* 2011;17:1791–1798.
- Glasner C, Albiger B, Buist G, et al. Carbapenemase-producing Enterobacteriaceae in Europe: a survey among national experts from 39 countries, February 2013. *Euro Surveill* 2013;18(28):pii = 20525.
- Hidron AI, Edwards JR, Patel J, et al. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006–2007. *Infect Control Hosp Epidemiol* 2008;29:996–1011.
- Hirsch EB, Tam VH. Detection and treatment options for *Klebsiella pneumoniae* carbapenemases (KPCs): an emerging cause of multidrug-resistant infection. *J Antimicrob Chemother* 2010;65:1119–1125.
- Van Duin D, Kaye KS, Neuner EA, Bonomo RA. Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomes. *Diagn Microbiol Infect Dis* 2013;75:115–120.
- Patel G, Huprikar S, Factor SH, Jenkins SG, Calfee DP. Outcomes of carbapenem-resistant *Klebsiella pneumoniae* infection and the impact of antimicrobial and adjunctive therapies. *Infect Control Hosp Epidemiol* 2008;29:1099–1106.

9. Borer A, Saidel-Odes L, Riesenberk K, et al. Attributable mortality rate for carbapenem-resistant *Klebsiella pneumoniae* bacteremia. *Infect Control Hosp Epidemiol* 2009;30:972–976.
10. Center for Disease Control and Prevention. Guidance for control of infections with carbapenem-resistant or carbapenemase-producing Enterobacteriaceae in acute care facilities. *MMWR* 2009;58:256–260.
11. Schwaber MJ, Lev B, Israeli A, et al. Containment of a country-wide outbreak of carbapenem-resistant *Klebsiella pneumoniae* in Israeli hospitals via a nationally implemented intervention. *Clin Infect Dis* 2011;52:848–855.
12. Ciobotaro P, Oved M, Nadir E, Bardenstein R, Zimhony O. An effective intervention to limit the spread of an epidemic carbapenem-resistant *Klebsiella pneumoniae* strain in an acute care setting: From theory to practice. *Am J Infect Control* 2011;39:671–677.
13. Schwaber MJ, Carmeli Y. An ongoing national intervention to contain the spread of carbapenem-resistant Enterobacteriaceae. *Clin Infect Dis* 2013, doi:10.1093/cid/cit795.
14. Ben-David D, Maor Y, Keller N, et al. Potential role of active surveillance in the control of a hospital-wide outbreak of carbapenem-resistant *Klebsiella pneumoniae* infection. *Infect Control Hosp Epidemiol* 2010;31:620–626.
15. Marchaim D, Chopra T, Perez F, et al. Outcomes and genetic relatedness of carbapenem-resistant enterobacteriaceae at Detroit medical center. *Infect Control Hosp Epidemiol* 2011;32:861–871.
16. Neuner EA, Yeh J-Y, Hall GS, et al. Treatment and outcomes in carbapenem-resistant *Klebsiella pneumoniae* bloodstream infections. *Diagn Microbiol Infect Dis* 2011;69:357–362.
17. Emerson CB, Eyzaguirre LM, Albrecht JS, Comer AC, Harris AD, Furuno JP. Healthcare-associated infection and hospital readmission. *Infect Control Hosp Epidemiol* 2012;33:539–544.
18. Won SY, Munoz-Price LS, Lolans K, Hota B, Weinstein RA, Hayden MK. Emergence and rapid regional spread of *Klebsiella pneumoniae* carbapenemase-producing Enterobacteriaceae. *Clin Infect Dis* 2011;53:532–540.
19. Souli M, Galani I, Antoniadou A, et al. An outbreak of infection due to beta-lactamase *Klebsiella pneumoniae* carbapenemase 2-producing *K. pneumoniae* in a Greek University Hospital: molecular characterization, epidemiology, and outcomes. *Clin Infect Dis* 2010;50:364–373.
20. Landman D, Salvani JK, Bratu S, Quale J. Evaluation of techniques for detection of carbapenem-resistant *Klebsiella pneumoniae* in stool surveillance cultures. *J Clin Microbiol* 2005;43:5639–5641.
21. Schechner V, Straus-Robinson K, Schwartz D, et al. Evaluation of PCR-based testing for surveillance of KPC-producing carbapenem-resistant members of the Enterobacteriaceae family. *J Clin Microbiol* 2009;47:3261–3265.
22. Feldman N, Adler A, Molshatzki N, et al. Gastrointestinal colonization by KPC-producing *Klebsiella pneumoniae* following hospital discharge: duration of carriage and risk factors for persistent carriage. *Clin Microbiol Infect* 2013;19:E190–E196.
23. Hussein K, Raz-Pasteur A, Finkelstein R, et al. Impact of carbapenem resistance on the outcome of patients' hospital-acquired bacteraemia caused by *Klebsiella pneumoniae*. *J Hosp Infect* 2013;83:307–313.
24. Zimmerman FS, Assous M V, Bdolah-Abram T, Lachish T, Yinnon AM, Wiener-Well Y. Duration of carriage of carbapenem-resistant Enterobacteriaceae following hospital discharge. *Am J Infect Control* 2013;41:190–194.
25. Schechner V, Kotlovsky T, Tarabeia J, et al. Predictors of rectal carriage of carbapenem-resistant Enterobacteriaceae (CRE) among patients with known CRE carriage at their next hospital encounter. *Infect Control Hosp Epidemiol* 2011;32:497–503.
26. Ben-David D, Masarwa S, Navon-Venezia S, et al. Carbapenem-resistant *Klebsiella pneumoniae* in post-acute-care facilities in Israel. *Infect Control Hosp Epidemiol* 2011;32:845–853.
27. Samra Z, Bahar J, Madar-Shapiro L, Aziz N, Israel S, Bishara J. Evaluation of CHROMagar KPC for rapid detection of carbapenem-resistant Enterobacteriaceae. *J Clin Microbiol* 2008;46:3110–3111.
28. Anderson KF, Lonsway DR, Rasheed JK, et al. Evaluation of methods to identify the *Klebsiella pneumoniae* carbapenemase in Enterobacteriaceae. *J Clin Microbiol* 2007;45:2723–2725.
29. CLSI. *Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Third Informational Supplement* CLSI document M100-S23Wayne, PA: Clinical and Laboratory Standards Institute, 2013.
30. Norton D, McLaren R, Exton-Smith A. *An Investigation of Geriatric Nursing Problems in the Hospital*. Edinburgh: Churchill Livingstone, 1975.
31. Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. *Biometrics* 1986;42:121–130.
32. Hanley JA, Negassa A, Edwardes MD deB, Forrester JE. Statistical analysis of correlated data using generalized estimating equations: an orientation. *Am J Epidemiol* 2003;157:364–375.
33. Balla U, Malnick S, Schattner A. Early readmissions to the department of medicine as a screening tool for monitoring quality of care problems. *Medicine (Baltimore)* 2008;87:294–300.
34. Justo D, Vislapu N, Shvedov V, et al. Admission Norton scale scores (ANSS) correlate with rehabilitation outcome and length in elderly patients following hip arthroplasty. *Arch Gerontol Geriatr* 2011;53:e33–e36.
35. Gold A, Sever R, Lerman Y, Salai M, Justo D. Admission Norton scale scores (ANSS) and postoperative complications following hip fracture surgery in the elderly. *Arch Gerontol Geriatr* 2012;55:173–176.
36. Adler A, Gniadkowski M, Baraniak A, et al. Transmission dynamics of ESBL-producing *Escherichia coli* clones in rehabilitation wards at a tertiary care centre. *Clin Microbiol Infect* 2012;18:E497–E505.
37. Lim CJ, Cheng AC, Kennon J, et al. Prevalence of multidrug-resistant organisms and risk factors for carriage in long-term care facilities: a nested case-control study. *J Antimicrob Chemother* 2014, doi:10.1093/jac/dku077.
38. O'Sullivan NP, Keane CT. Risk factors for colonization with methicillin-resistant *Staphylococcus aureus* among nursing home residents. *J Hosp Infect* 2000;45:206–210.
39. McKinnell JA, Miller LG, Eells SJ, Cui E, Huang SS. A systematic literature review and meta-analysis of factors associated with methicillin-resistant *Staphylococcus aureus* colonization at time of hospital or intensive care unit admission. *Infect Control Hosp Epidemiol* 2013;34:1077–1086.
40. Day D. Keeping patients safe during intrahospital transport. *Crit Care Nurse* 2010;30:18–32.